Dianthus Therapeutics (DNTH) Current Deferred Revenue (2022 - 2025)

Dianthus Therapeutics' Current Deferred Revenue history runs 4 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• In Q4 2025, Current Deferred Revenue rose 148.02% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (up 148.02% YoY), while the FY2025 annual figure was $1.2 million, up 148.02% from the prior year.
• Current Deferred Revenue was $1.2 million for Q4 2025 at Dianthus Therapeutics, up from $954000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $1.2 million in Q4 2025 to a low of $100000.0 in Q4 2022.
• Historically, Current Deferred Revenue has averaged $407900.0 across 4 years, with a median of $289500.0 in 2022.
• The sharpest annual moves came in 2024 and 2025: Current Deferred Revenue changed 0.0% in 2024, then surged 854.0% in 2025.
• A 4-year view of Current Deferred Revenue shows it stood at $100000.0 in 2022, then changed by 0.0% to $100000.0 in 2023, then surged by 379.0% to $479000.0 in 2024, then surged by 148.02% to $1.2 million in 2025.
• The last three Current Deferred Revenue figures came in at $1.2 million (Q4 2025), $954000.0 (Q3 2025), and $479000.0 (Q2 2025), per Business Quant data.